Clinical Features of Severe Dementia: Function

Severe Dementia

Volumn , Issue , 2006, Pages 117-121

  Gauthier, Serge ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

ADL scales for moderate to severe dementia; Functional assessment staging; Functional autonomy decline in severe dementia; IADL and Basic ADL measurements; Impact on caregivers formal and informal

Indexed keywords

EID: 58049105557     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/0470010568.ch9     Document Type: Chapter

References (29)

1. Applegate WB, Blass JP, Williams TK (1990) Instruments for the functional assessment of older patients. N Eng J Med, 322:1207-1214.
2. Blessed G, Tomlinson RE, Roth M (1968) The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects. Brit J Psychiatry, 114:797-811.
3. Doody R, Wirth Y, Schmitt F, Möbius HJ (2004) Specific functional effects of memantine treatment in patients with moderate to severe Alzheimer's disease. Dement Geriatr Cogn Disord, 18:227-232.
4. Feldman H, Sauter A, Donald A et al. (2001) The Disability Assessment for Dementia scale. A 12 month study of functional ability in mild to moderate severity Alzheimer disease. Alzheimer Dis Assoc Disord, 15:89-95.
5. Feldman H, Gauthier S, Hecker J et al. (2001) A 24-week, randomised, double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology, 57:613-620.
6. Feldman H, Gauthier S, Hecker J et al. (2003) Efficacy of donepezil on maintenance of activities of daily living in patients with moderate to severe Alzheimer's disease and the effect on caregiver burden. JAGS, 51:737-744.
7. Feldman H, Gauthier S, Hecker J et al. (2005) Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomised, placebo-controlled trial. Int J Geriatr Psychiatry, 20:559-569.
8. Fern L (1974) Behavioral activities in demented geriatric patients. Gerontol Clin, 16:185-194.
9. Franssen EH, Kluger A, Torossian CL, Reisberg B. (1993) The neurologic syndrome of severe Alzheimer's disease. Arch Neurol, 50:1029-1039.
10. Galasko D, Bennett D, Sano M et al. (1997) An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. Alzheimer Dis Assoc Disord, 11(Suppl 2):S33-S39.
11. Galasko D, Edland SD, Morris JC et al. (1995) The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part XI. Clinical milestones in patients with Alzheimer's disease followed over 3 years. Neurology, 45:1451-1455.
12. Gauthier S, Bodick N, Erzigkeit E et al. (1997) Activities of daily living as an outcome measure in clinical trials of dementia drugs. Alzheimer Dis Assoc Disord, 11(Suppl 3):6-7.
13. Gauthier S, Rockwood K, Gélinas I et al. (1999) Outcome measures for the study of activities of daily living in vascular dementia. Alzheimer Dis Assoc Disord, 13(Suppl 3):S143-S147.
14. Gélinas I, Gauthier L, McIntyre M, Gauthier S (1999) Development of a functional measure for persons with Alzheimer's disease: the Disability Assessment for Dementia. Am J Occup Therapy, 53:471-481.
15. Green CR, Mohs RC, Schmeidler J et al. (1993) Functional decline in Alzheimer's disease: a longitudinal study. JAGS, 41:654-661.
16. Jones R (2004) Management of comorbidity in Alzheimer's disease. In Alzheimer's Disease and Related Disorders Annual S. Gauthier, P. Scheltens, JL Cummings (Eds), 145-160.
17. Katz S, Ford AB, Moskowitz RW et al. (1963) Studies of illness in the aged: the index of ADL, a standardised measure of biological and psychological function. JAMA, 185:914-919.
18. Kempen G, Steverink N, Ormel J, Deeg D (1996) The assessment of ADL among frail elderly in an interview survey: self-report versus performance-based tests and determinants of discrepancies. J Gerontology, 51B:P254-P260.
19. Lawton MP, Bordy EM (1969) Assessment of older people: self maintaining and instrumental activities of daily living. Gerontologist, 9:179-186.
20. Mahoney F, Barthel DW (1965) Functional evaluation: the Barthel Index. Md Med J, 14:61-65.
21. Ostbye T, Tyas S, McDowell I, Koval J (1997) Reported activities of daily living: agreement between eldferly subjects with and without dementia and their caregivers. Age and Aging, 26:99-106.
22. Reisberg B (1988) Functional Assessment Staging (FAST). Psychopharmacol Bulletin, 24:653-659.
23. Reisberg B, Doody R, Stöffler A et al. (2003) Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med, 348:1333-1341.
24. Sano M, Ernesto C, Thomas RG et al. (1997) A controlled study of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. N Engl J Med, 336:1216-1222.
25. Suh GH, Ju YS, Yeon BK, Shah A. A (2004) longitudinal study of Alzheimer's disease: rates of cognitive and functional decline. Int J Geriatr Psychiatry, 19:817-824.
26. Tariot PN, Cummings JL, Katz IR et al. (2001) A randomised, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home. JAGS, 49:1590-1599.
27. Tariot PN, Farlow MR, Grossberg GT et al. (2004) Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil. JAMA, 291:317-324.
28. Winblad B, Wimo A, Möbius HJ, Fox JM, Fratiglioni L. (1999) Severe dementia: a common condition entailing high costs at individual and societal levels. Int J Geriat Psychiatry, 14:911-914.
29. Winblad B, Poritis N (1999) Memantine in severe dementia: results of the 9M-BEST Study (Benefit and Efficacy in Severely demented patients during Treatment with memantine). Int J Geriat Psychiatry, 14:135-146.